Full Press Release Details
Bicycle Therapeutics Enhances Leadership Team
with Key Appointments
Arroyo, M.D., Ph.D., appointed Chief Development Officer
Perry, Pharm.D., promoted to Senior Vice President, Commercial
CAMBRIDGE, England & BOSTON, April 3,
2023 - Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics
based on its proprietary bicyclic peptide (Bicycle ) technology, today announced
the appointment of Santiago Arroyo, M.D., Ph.D., as Chief Development Officer, effective March 31. In addition, Jennifer Perry, PharmD,
has been promoted to Senior Vice President, Commercial.
Dr. Arroyo brings to Bicycle over 20 years
of biopharmaceutical industry experience, leading the clinical development of therapeutics across multiple disease areas. He was previously
Chief Medical Officer at Momenta Pharmaceuticals, which was acquired by Johnson & Johnson in 2020. Dr. Arroyo will be responsible
for overseeing all aspects of the pipeline as it continues to expand and advance and as the company prepares to transition into late-stage
clinical development. Ms. Perry will be responsible for establishing and growing the commercial organization.
"We are thrilled to have Santiago on board
in the new role of Chief Development Officer at Bicycle as we prepare to transition into a late-stage development organization,"
said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics. "At Momenta, he was key in the development of nipocalimab,
an anti-FcRn antibody and his expertise will be invaluable in guiding all aspects of clinical development as we move our multiple programs
forward within oncology and beyond. With Santiago as CDO and Jennifer in her commercial role, we believe we are setting ourselves up for
success as we advance BT8009, BT5528, and BT7480 in the clinic."
"I am eager to be joining Bicycle at this
exciting time for the company," said Dr. Arroyo, Chief Development Officer of Bicycle Therapeutics. "Bicycles are
a novel technology that represent a potentially impactful new treatment option for patients with cancer and other life-threatening diseases.
I am impressed with the work the clinical team has done to date. I look forward to building the development team and to working closely
with Kevin and the rest of the Bicycle team to advance the company's broad and promising pipeline."
In conjunction with Dr. Arroyo's appointment, Dr. Dominic
Smethurst, Chief Medical Officer, has decided to leave the company. "I would like to thank Dom for his contributions to Bicycle."
said Kevin Lee. "We wish him every success in his future endeavors."
Dr. Arroyo was most recently the Chief Medical
Officer of Fulcrum Therapeutics. Previously, he was Chief Medical Officer of Momenta Pharmaceuticals, leading the Company's clinical
development programs until Momenta's acquisition by Johnson & Johnson for $6.5 billion in 2020. As Chief Medical Officer
at Momenta, Dr. Arroyo led the clinical development of the company's portfolio of hematology, neurology, immunology, and materno-fetal
therapeutics. Previously, he was the Chief Medical Officer of Boston Pharmaceuticals and before that held multiple senior clinical development
leadership roles at leading pharmaceutical companies. Dr. Arroyo served as Senior Vice President, Head of Clinical Research and Chief
Medical Officer of Pharmatherapeutics at Pfizer, Inc. and was therapeutic area head for neurosciences, discovery medicine and clinical
pharmacology at Bristol-Myers Squibb. Earlier, Dr. Arroyo held clinical development roles at Eisai Global Clinical Development and
Schwarz Biosciences. Dr. Arroyo was an Instructor at the Johns Hopkins Medical School, Associate Professor at the Medical College
of Wisconsin and Senior Specialist at the Hospital Clinic of Barcelona. He earned a Ph.D. from the Universidad de Barcelona and an M.D.
from the Universidad Auton ma de Madrid.
Ms. Perry has over 20 years of experience
in pharma and biotech with 15 years in oncology. She has devoted much of her career to building and leading oncology teams focused on
the critical steps to commercialization. Her experience spans commercial and medical roles with a focus on go-to-market strategies for
launching oncology medicines at GSK, Tesaro, TG Therapeutics and Pharmacyclics. Most recently, she built and led U.S. oncology sales teams
for hematology and solid tumors at TG Therapeutics and at GSK/Tesaro with responsibility for leading the customer-selling strategy and
driving the achievement of U.S. sales targets. She earned an undergraduate degree from Loyola University Chicago and a PharmD from University
of Illinois Chicago.
About Bicycle Therapeutics
Bicycle Therapeutics (NASDAQ: BCYC) is a clinical-stage
biopharmaceutical company developing a novel class of medicines, referred to as Bicycles, for diseases that are underserved by existing
therapeutics. Bicycles are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize
their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycles attractive
candidates for drug development. Bicycle is evaluating BT5528, a second-generation Bicycle Toxin Conjugate (BTC ) targeting EphA2;
BT8009, a second-generation BTC targeting Nectin-4, a well-validated tumor antigen; and BT7480, a Bicycle TICA targeting Nectin-4
and agonizing CD137, in company-sponsored Phase I/II trials. In addition, BT1718, a BTC that targets MT1-MMP, is being investigated in
an ongoing Phase I/IIa clinical trial sponsored by the Cancer Research UK Centre for Drug Development. Bicycle is headquartered in Cambridge,
UK, with many key functions and members of its leadership team located in Cambridge, MA. For more information, visit bicycletherapeutics.com.
Forward Looking Statements
This press release may contain forward-looking
statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements may be
identified by words such as "aims," "anticipates," "believes," "could," "estimates,"
"expects," "forecasts," "goal," "intends," "may," "plans," "possible,"
"potential," "seeks," "will" and variations of these words or similar expressions that are intended
to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in
this press release include, but are not limited to, statements regarding the advancement and expansion of Bicycle's pipeline and
Bicycle's transition to a late-stage development organization. Bicycle may not actually achieve the plans, intentions or expectations
disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results
or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result
of various factors, including: the risk that Bicycle may not successfully advance any product candidate in its pipeline; the risk that
Bicycle may not be able to identify and develop any additional product candidates to expand its pipeline; the risk that Bicycle may not
progress any of its programs into late-stage clinical development; and other important factors, any of which could cause Bicycle's
actual results to differ from those contained in the forward-looking statements, are described in greater detail in the section entitled
"Risk Factors" in Bicycle's Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC)
on February 28, 2023, as well as in other filings Bicycle may make with the SEC in the future. Any forward-looking statements contained
in this press release speak only as of the date hereof, and Bicycle expressly disclaims any obligation to update any forward-looking statements
contained herein, whether because of any new information, future events, changed circumstances or otherwise, except as otherwise required
SVP, Capital Markets & Corporate Communications